Relmada Therapeutics, Inc. RLMD Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s net gains (losses) on investments?
- Relmada Therapeutics, Inc. (RLMD) reported net gains (losses) on investments of -$540.1K in Q1 2026.
- How has Relmada Therapeutics, Inc.'s net gains (losses) on investments changed year-over-year?
- Relmada Therapeutics, Inc.'s net gains (losses) on investments decreased by 446.8% year-over-year, from $155.73K to -$540.1K.
- What is the long-term trend for Relmada Therapeutics, Inc.'s net gains (losses) on investments?
- Over 3 years (2021 to 2025), Relmada Therapeutics, Inc.'s net gains (losses) on investments has grown at a -13.3% compound annual growth rate (CAGR), from -$611.38K to $398.25K.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.